In This Article What Does Research Show About GLP-1 Safety
[15] [16] Constipation paradoxically affects 10-20% of patients, demonstrating that GLP-1 medications can slow bowel transit to varying degrees in different individuals
The Future of Retatrutide Dosing Retatrutide remains in Phase III clinical trials, and final FDA-approved dosing guidelines will likely evolve as additional long-term data emerges
About 48% of HIV-infected individuals are alcohol abusers, which tremendously potentiates HIV-induced hepatotoxicity, leading to progressive liver damage, fibrosis, and cirrhosis
However, some studies have reported contradictory evidences
These larger, longer-duration studies will provide the comprehensive safety and efficacy data needed for FDA review